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Oxidative Stress in Human Coronary Artery Disease
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Bartlomiej Guzik, MD, PHD,† Heinrich E. Lob, PHD,* Deepa Mangalat, MD,* Nyssa Hoch, PHD,*
Sergey Dikalov, PHD,* Pawel Rudzinski, MD, PHD,† Boguslaw Kapelak, MD, PHD,†
Jerzy Sadowski, MD, PHD,‡ David G. Harrison, MD, FACC*
Atlanta, Georgia; and Cracow, Poland
Objectives This study sought to examine the expression and activity of the calcium-dependent nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidase (NOX) in human atherosclerotic coronary arteries.
Background The NOX-based NADPH oxidases are major sources of reactive oxygen species (ROS) in human vessels. Several
NOX homologues have been identified, but their relative contribution to vascular ROS production in coronary ar-
tery disease (CAD) is unclear; NOX5 is a unique homolog in that it is calcium dependent and thus could be acti-
vated by vasoconstrictor hormones. Its presence has not yet been studied in human vessels.
Methods Coronary arteries from patients undergoing cardiac transplantation with CAD or without CAD were studied; NOX5
was quantified and visualized using Western blotting, immunofluorescence, and quantitative real-time polymer-
ase chain reaction. Calcium-dependent NADPH oxidase activity, corresponding greatly to NOX5 activity, was
measured by electron paramagnetic resonance.
Results Both Western blotting and quantitative real-time polymerase chain reaction indicated a marked increase in
NOX5 protein and messenger ribonucleic acid (mRNA) in CAD versus non-CAD vessels. Calcium-dependent
NADPH-driven production of ROS in vascular membranes, reflecting NOX5 activity, was increased 7-fold in CAD
and correlated significantly with NOX5 mRNA levels among subjects. Immunofluorescence showed that NOX5
was expressed in the endothelium in the early lesions and in vascular smooth muscle cells in the advanced
coronary lesions.
Conclusions These studies identify NOX5 as a novel, calcium-dependent source of ROS in atherosclerosis. (J Am Coll
Cardiol 2008;52:1803–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.063d
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(therosclerosis and its risk factors increase vascular produc-
ion of reactive oxygen species (ROS), which in turn
ontribute to many aspects of atherosclerotic lesion forma-
ion (1). A major source of ROS in atherosclerosis is the
icotinamide adenine dinucleotide phosphate (NADPH)
xidases (2). The catalytic subunits of the NADPH oxidases
re the nicotinamide adenine dinucleotide phosphate oxi-
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ccepted July 14, 2008.ase (NOX) proteins, which are involved in the transfer of
lectrons from NADPH to heme groups and ultimately
olecular oxygen to form superoxide (O2
·) (2). The
OX-based NADPH oxidases are major sources of ROS in
uman vasculature. There are various homologues of NOX
roteins, and their expression in atherosclerotic lesions
aries depending on location and stages of development
See page 1810
3,4). Particularly, the role of NOX2 and NOX4 and, to a
esser extent, NOX1 have been described in the context of
uman atherosclerosis and coronary artery disease (CAD)
3–5). The last discovered of these is NOX5, which is
nique because it contains EF hand domains in the
m
N
p
h
R
h
o
A
o
o
s
s
f
c
M
P
a
u
C
(
a
t
C
d
m
t
o

M
g
m
c
U
d
2
p
t
n
t
m
m
T
s
p
t
C
C
e
d
C
C
D
t
1
p
T
c
c
T
d
s
I
i
c
d
p
w
(
u
C
*
1804 Guzik et al. JACC Vol. 52, No. 22, 2008
NOX5 in Atherosclerosis November 25, 2008:1803–9N-terminal region that bind cal-
cium and permit activation of the
enzyme by increases in intracellu-
lar calcium ([Ca]i) (6). Research
has identified NOX5 in immune
tissues, testes, and cancer cells (6),
and recently in human endothelial
cells (7). Although NOX5 has
been identified in endothelium, its
activity and contribution to ROS
production in native endothelial
cells or human blood vessels re-
main unclear because all experi-
ents were conducted on cells transfected with exogenous
OX5 (7). Thus the potential role of calcium-dependent ROS
roduction in human CAD remains unknown. Interestingly, it
as been reported that calcium channel antagonists reduce
OS production in human endothelial cells (8). These drugs
ave been shown to be clinically beneficial in improving clinical
utcomes in patients with vascular diseases, particularly CAD.
lthough there are other potential calcium-dependent sources
f ROS in endothelial cells, given a key role of NADPH
xidases, it is possible that NOX5 may contribute to oxidative
tress in the setting of vascular disease. The aim of the present
tudy was therefore to determine whether expression and
unction of NOX5 is increased in human atherosclerotic
oronary arteries compared with nonatherosclerotic vessels.
ethods
atients and blood vessels. Segments of human coronary
rteries were obtained from explanted hearts of 26 patients
ndergoing heart transplantation for end-stage heart failure.
ollection of tissues was performed as previously described
3). The Ethics Committee at the University of Cracow
pproved collection of tissues. Informed consent was ob-
ained from each subject.
alcium-dependent NADPH oxidase activity. Calcium-
ependent NADPH oxidase activity was measured from
embrane fractions of human coronary arteries using elec-
ron paramagnetic spin resonance by measuring production
f ROS as described previously (9) on stimulation with 100
M NADPH in the presence and absence of 1 mM Ca.
embrane fractions were prepared by a 2-h ultracentrifu-
ation of vascular homogenates at 200,000 g. Twenty
icrograms of membrane fractions were suspended in
alcium-free media A with 1 mmol/l acetoamidophenol, 5
/ml horseradish peroxidase, 50 U/ml Cu/Zn-superoxide
ismutase, and 1 mmol/l 1-hydroxy-4-phosphono-oxy-
,2,2,6 tetraethylpiperidine-HCl. The reaction mixture was
laced in a 100-l electron spin resonance (ESR) capillary
ube with 100 M NADPH, and accumulation of the PP·
itroxide was measured using a Bruker EMX ESR spec-
rometer (Billerica, Massachusetts) and a super-high Q
icrowave cavity as previously described (9). All measure-
Abbreviations
and Acronyms
CAD  coronary artery
disease
NADPH  nicotinamide
adenine dinucleotide
phosphate
NOX  nicotinamide
adenine dinucleotide
phosphate oxidase
ROS  reactive oxygen
speciesents were performed at 25°C using a Bruker Nitrogen
c
iemperature Controller system with the following ESR
ettings: microwave frequency 9.46 GHz, modulation am-
litude 2 G, microwave power 10 dB, conversion time 1.3 s,
ime constant 5.2 s. Measurements were performed in both
a-free media and also in media A containing 1 mM
a. The NADPH-driven ROS production in the pres-
nce of Ca was used to determine total NADPH oxi-
ase activity, and the difference between total and
a-independent oxidase activity was calculated as
a-dependent NADPH oxidase activity.
etection of NOX5 protein. Twenty micrograms of
otal protein from vascular homogenates was separated by
2% sodium dodecyl sulfate polyacrylamide gel electro-
horesis and transferred to nitrocellulose membranes.
he NOX5 protein was detected using a rabbit poly-
lonal antibody raised against the NOX5 second extra-
ellular loop peptide EASPFQFWELLLTTRPGIG.
his is common to all NOX5 splice variants. Bands were
etected using chemiluminescence as previously de-
cribed and analyzed using National Institutes of Health
mage software (Bethesda, Maryland).
For detection of NOX5 protein in histological sections,
mmunofluorescence was performed on frozen 7-m optical
utting temperature (OCT)-embedded tissue sections as
escribed previously. The NOX5 was visualized using rabbit
olyclonal anti-NOX5 (1:100 dilution). Endothelial cells
ere identified using a mouse monoclonal anti-CD31
1:200 dilution). Appropriate secondary antibodies were
sed. Sections treated with secondary antibodies alone did
linical Characteristics of Studied Patients
Table 1 Clinical Characteristics of Studied Patients
No CAD CAD
n 12 14
Age, yrs (mean  SEM) 46.3 5.6 50.3 2.9
Male:female 10:2 13:1
Risk factors
Smoking, n (%) 3 (25) 4 (28)
Hypertension, n (%) 2 (16) 12 (86)*
Diabetes, n (%) 0 (0) 2 (15)
Hypercholesterolemia, n (%) 2 (16) 9 (65)*
Body mass index, kg/m2 22.5 1.2 27.2 0.9*
Cholesterol, mmol/l (mean  SEM) 4.9 0.7 5.2 0.6
Fasting glucose, mmol/l (mean  SEM) 5.0 0.3 5.6 0.2*
MI/CABG, n (%) 0 (0) 11 (78)*
PAD/TIA, n (%) 0 (0) 12 (86)*
Ejection fraction (%) 17.0 7.2 18.2 2.3
Medications
Aspirin 3 (25) 4 (28)
Beta-blocker 6 (50) 7 (50)
HMG-CoA reductase inhibitor 0 (0) 8 (55)*
Digoxin 4 (33) 6 (42)
ACEI 9 (75) 10 (70)
Ca channel blockers 0 (0) 0 (0)
p  0.05 versus No CAD group.
ACEI  angiotensin-converting enzyme inhibitor; CABG  coronary artery bypass graft; CAD oronary artery disease; HMG-CoA  3-hydroxy-3-methylglutaryl coenzyme A; MI  myocardial
nfarction; PAD  peripheral arterial disease; TIA  transient ischemic attack.
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November 25, 2008:1803–9 NOX5 in Atherosclerosisot show specific staining. Staining was visualized on a
onfocal microscope.
etection of NOX5 messenger ribonucleic acid (mRNA)
y quantitative real-time reverse-transcriptase polymer-
se chain reaction. For detection of NOX5 mRNA, seg-
ents of coronary arteries were snap-frozen in tri-reagent
nd total ribonucleic acid (RNA) was isolated using the
NAeasy (Qiagen, Valencia, California) kit with DNAse
igestion (4). The complementary deoxyribonucleic acid
cDNA) was synthesized using a High Capacity cDNA
everse Transcription kit (Applied Biosystems, Foster City,
alifornia) and was subjected to quantitative polymerase
hain reaction using the TaqMan ddCT method (Applied
iosystems) and ABI 7500 Fast Real-Time PCR system
Applied Biosystems). All primers and probes (NOX5:
[G] 3470 3480 3490 3500 35
Ca-free 
100uM NADPH 
1mM Ca++ 
100uM NADPH 
Control siRNA A 
B 
Nox5 
actin 
control siNox5 
7
5
* 
Figure 1 Contribution of NOX5 to Calcium-Dependent NADPH O
(A) Example ESR spectra of nitroxide adduct formation by membranes prepared fr
1 mM Ca (left) and the effects of small interfering ribonucleic acid (siRNA) aga
protein in HAECs; n  4 experiments. (C) Average Ca-dependent (top) and Ca
(solid bars) and NOX5 siRNA (open bars). n  4. Values are presented as mean
nicotinamide adenine dinucleotide phosphate.s00225846_m1 gene expression assay as well as an 18S
ndogenous control) were from Applied Biosystems.
uppression of NOX5 using small interfering ribonucleic
cid (siRNA). The NOX5 siRNA OnTargetPlus (Dharmacon,
afayette, Colorado) and OnTarget Plus siControl were pre-
ncubated in Eppendorf tubes containing 0.572 ml Opti-MEM
nd 24 l Oligofectamine (both from Invitrogen Corporation,
arlsbad, California) per sample. The siRNA was added at a
nal volume of 3 ml to pre-confluent human aortic endothelial
ells (Lonza, Walkersville, Maryland) (final concentration of
iRNA, 100 nmol/l). After 4 to 6 h of incubation at 37°C and
% CO2, 6 ml endothelial basal medium-2 media was added.
his procedure was repeated after 48 h.
tatistical analysis. All data are expressed as mean SEM
ith n equal to the number of patients. Comparisons
520 
Nox5 siRNA 
[G] 3470 3480 3490 3500 3510 3520 
C 
a 
a * 
e Activity in Human Endothelial Cells
man aortic endothelial cells (HAECs) in Ca-free media and in the presence of
X5 on calcium-dependent signal (right). (B) Effects of siRNA NOX5 on NOX5
pendent (bottom) NADPH oxidase activity in the presence of control siRNA
. *p  0.01 versus control siRNA. ESR  electron spin resonance; NADPH 10 3
5kD
0kD
xidas
om hu
inst NO
-inde
 SEM
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NOX5 in Atherosclerosis November 25, 2008:1803–9etween groups of patients or treatments were made using
he Student t test or Mann-Whitney U test. Correlation
etween oxidase activity and NOX5 expression was assessed
y Spearman correlation coefficient. Values of p  0.05
ere considered statistically significant.
esults
haracteristics of patients studied. Subjects included in
his study had end-stage heart failure and were undergoing
eart transplantation. Fourteen individuals had CAD, and
2 patients had either dilated (n 11) or hypertrophic (n
) cardiomyopathy, but did not have CAD. The diagnosis
f CAD was based on either a history of myocardial
nfarction or on coronary angiography. As expected, demo-
raphic and clinical characteristics indicated that CAD
atients had more risk factors for atherosclerosis than
on-CAD patients and were more likely taking statins.
imilarly, the presence of CAD was associated with a
reater incidence of prior myocardial infarction, transient
schemic attack, and peripheral arterial disease. The degree
A 
B p=0.01 
* 
Figure 2 Calcium-Dependent NADPH Oxidase Activity and NOX
(A) Calcium-independent (left) and -dependent (right) NADPH oxidase activity in h
The NADPH oxidase activity was measured by ESR as described in the Methods se
out (n  8) CAD. (B) The NOX5 messenger ribonucleic acid (mRNA) expression in
time polymerase chain reaction analysis was performed using commercially availa
oxidase activity and NOX5 mRNA expression in studied coronary arteries. Data we
CAD. Abbreviations as in Figure 1.f left ventricular dysfunction, as reflected by the ejection
raction, was similar between the 2 groups (Table 1).
alcium-dependent NADPH oxidase activity in human
ndothelial cells and coronary arteries. As an initial
ttempt to quantify NOX5 activity and protein levels in
ascular segments, we studied human endothelial cells to
alidate our assay and antibody (Fig. 1). Western blots using
he rabbit polyclonal antibody showed a single band at a
olecular weight of approximately 70 kDa, in keeping with
he reported molecular weight of the  isoform of NOX5.
mportantly, siRNA against NOX5 reduced this band by
5%, whereas scrambled siRNA had no significant effect.
sing ESR, we detected NADPH-driven ROS production
n membranes of human endothelial cells that was greater in
he presence of calcium than in its absence. The difference
etween these 2, that is, the calcium-dependent NADPH
xidase activity, was reduced by siRNA against NOX5.
hese data strongly suggest that studies of membranes from
uman endothelial cells in the presence and absence of
alcium can reflect NOX5 activity. We recognize that
C 
Rs=+0.66; p<0.01 
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coronary arteries in relation to the presence of coronary artery disease (CAD).
in membranes isolated from coronary arteries of subjects with (n  8) and with-
ry arteries from patients with (n  13) and without (n  11) CAD. TaqMan real-
e expression assays. (C) Relationship between Ca-dependent NADPH
ressed as mean  SEM. *p  0.05 versus non-CAD. **p  0.01 versus non-5 Exp
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November 25, 2008:1803–9 NOX5 in Atherosclerosisalcium can activate protein kinase C, which can contribute
o activation of NOX2 and perhaps other NOX proteins, by
hosphorylation of p47phox. In addition, calcium can serve to
ctivate ROS from xanthine oxidase and the mitochondria;
owever, these events require the presence of cytoplasmic
roteins that were absent in this assay. The fact that
iNOX5 reduced the calcium-dependent NADPH oxidase
ctivity to approximately the same degree as it reduced
OX5 protein levels suggests that NOX5 is the source of
OS under the conditions of this assay.
As observed in endothelial cells, membrane preparations
f all of the studied coronary arteries showed NADPH-
riven ROS production both in the absence and in the
resence of calcium. The ROS production in the absence of
alcium, reflecting the activity of NOX1, NOX2, and
OX4, was significantly greater in membranes from CAD
han in non-CAD subjects (Fig. 2A). Interestingly, the
ncrease in calcium-dependent NADPH oxidase activity
as significantly more pronounced, averaging 7- to 8-fold
ore in vascular membranes from CAD subjects compared
ith non-CAD subjects (Fig. 2A, right panel).
OX5 mRNA expression and correlation with calcium-
ependent NADPH oxidase activity. Real-time polymer-
se chain reaction showed the presence of NOX5 mRNA in
ll vascular segments; however, its levels were much greater
n homogenates of vessels from CAD compared with
on-CAD subjects (Fig. 2B). Importantly there was a very
ignificant relationship between these levels of NOX5
RNA and the calcium-dependent NADPH oxidase activ-
ty (Fig. 2C). These findings strongly suggest that, as in the
ase of cultured endothelial cells, in human coronary arter-
es, NOX5 contributes to calcium-dependent NADPH
xidase activity.
etection of NOX5 protein in human coronary arteries. To
uantify NOX5 protein, we performed Western blots on
omogenates of coronary arteries from CAD and non-
AD patients. As in cultured human endothelial cells,
estern blotting showed a single band at a molecular
eight of 70 kDa, compatible with the beta isoform of
OX5, and an identical size to the band observed in
ndothelial cells and DU145 cells (Fig. 3A). More impor-
antly, this was increased by 4-fold in CAD compared with
on-CAD segments.
To confirm this and to attempt to localize NOX5 in
therosclerotic lesions, we performed immunofluorescence
taining using the antibody we developed. These studies
orroborated that NOX5 in expression was very low in
oronary arteries from subjects without CAD (Fig. 4A), but
hat CAD vessels showed specific staining. In the vessels
rom CAD subjects but in the absence of plaque, NOX5
xpression seemed most prominent in endothelial cells, as
videnced by costaining with anti-CD31 (Figs. 4B and 4C).
n more advanced lesions, with moderate neointima, NOX5
taining was most striking in the neointima, although
unctate staining could also be observed in the inner aspects
f the media (Fig. 4D). The most complex lesions showed fntense costaining of NOX5 with smooth muscle underlying
dvanced plaques (Fig. 4E). In no instance did we observe
olocalization of NOX5 with T-cell marker CD3 or mac-
ophage marker CD68 (data not shown).
iscussion
n this report, we show that NOX5 protein and mRNA
xpression are markedly increased in vessels of patients with
AD compared with non-CAD subjects. This is associated
ith increased calcium-dependent membrane NADPH ox-
dase activity, characteristic of NOX5. Indeed, we find that
he level of calcium-dependent NADPH oxidase activity
orrelates significantly with NOX5 mRNA when compared
etween individual patients. Our immunostaining confirmed
he increase in NOX5 protein and shows that its presence
eems to vary depending on the stage of atherosclerosis.
Our study is the first to describe the presence of calcium-
ependent NADPH oxidase activity in human vasculature.
e used an electron spin resonance-based assay to detect
alcium-dependent NADPH oxidase activity based on a
odification of recently published methodology (9). The
onditions of this assay allow detection of hydrogen perox-
de by taking advantage of the formation of compound II
Figure 3 NOX5 Expression in Human
Coronary Arteries in Relation to CAD
Example Western blots (A), average data showing NOX5 protein expression in
non–coronary artery disease (CAD) (n  7) and CAD (n  7) coronary arteries
(B). Lysates of DU 145 prostate cancer cells were used as positive control.
Bars represent mean  SEM. *p  0.01. Abbreviations as in Figure 1.rom horseradish peroxidase, which in turn reacts with
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NOX5 in Atherosclerosis November 25, 2008:1803–9cetoamidophenol, forming a radical that reacts with the
itroxide spin probe. In numerous preliminary experiments,
e were unable to detect calcium-dependent superoxide
ormation from membrane fractions of endothelial cells or
uman coronary arteries using ESR. This was surprising
ecause NOX5, like other NOX proteins, contains heme
roups that should perform a one-electron reduction of
xygen, and should therefore form superoxide. It is possible,
owever, that NOX5 shares similarity with NOX4, which
eems to predominantly release hydrogen peroxide (10).
his might be attributable to positive charges near the heme
roups, which retain the negatively charged superoxide until
t undergoes spontaneous dismutation to hydrogen perox-
de. It is also likely that the membranes we prepared
ontained extracellular superoxide dismutase, which is
nown to be present in large amounts in the vasculature
11). This enzyme binds to components of the extracellular
atrix, which was almost certainly included in our mem-
rane preparations and could rapidly convert superoxide to
ydrogen peroxide, preventing detection of the former.
rior reports have reported that NOX5 produces both
ydrogen peroxide and superoxide using fluorescent meth-
ds; however, these studies used overexpression of the
nzyme and did not compare the relative amounts of
ydrogen peroxide versus superoxide formed (7,12). Hydro-
en peroxide plays an important role in cell signaling and
A B 
E 
NI 
D 
CD31 
CD31
Figure 4 NOX5 Localization in Human CAD at Different Stages
Immunofluorescent localization of NOX5 in human coronary arteries. The NOX5 (re
coronary artery segments from CAD patients showing no atherosclerosis (B,C), in
segments with severe complex lesions (E). (C) A magnification of (B) showing the
endothelial cell marker CD31 in (A to D) and smooth muscle cell alpha actin (E).
Abbreviations as in Figure 1.lso contributes to atherosclerosis, because transgenic mice flhat overexpress catalase are protected from lesion develop-
ent (13). Thus, the formation of hydrogen peroxide by
OX5 could have important implications for the genesis of
ascular disease.
Our present observations have implications for mecha-
isms underlying alterations of vascular function in CAD.
asoactive agonists increase [Ca]i both in the endothelial
nd vascular smooth muscle cells. In endothelial cells, this
romotes release of nitric oxide (NO), whereas in vascular
mooth muscle cells, increases in intracellular calcium trig-
er the contractile apparatus (14). The induction of NOX5
n the endothelium could negate release of NO from the
ndothelium by permitting the simultaneous production of
uperoxide and hydrogen peroxide. The former reacts with
O at a diffusion-limited rate, leading to loss of NO and
ormation of peroxynitrite (15), and these mechanisms are
nhanced in human atherosclerosis (16). Hydrogen peroxide
an also participate in consumption of NO via reactions
ith peroxidases (17). The induction of NOX5 in the
ascular smooth muscle could also lead to loss of NO as it
iffuses into these cells. Moreover, ROS such as peroxyni-
rite can alter function of the sarcoplasmic reticulum,
eading to increases in vascular smooth muscle [Ca]i (18).
dditionally, recent studies in Drosophila have shown
hat the fruit-fly homolog of NOX5 can contribute to
mooth muscle cell contraction in response to calcium
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CD31 CD31 
-SMA 
herosclerosis
studied in control, non-coronary artery disease (CAD) coronary arteries (A), in
ry artery segments showing neointimal hyperplasia (D), and in coronary artery
nce of NOX5 in endothelium (double staining; arrows). Green staining represents
raphs show representative staining of at least 5 independent experiments.E 
of At
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Microgux (19). Together, these events would promote vaso-
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November 25, 2008:1803–9 NOX5 in Atherosclerosisonstriction and could alter vascular responses to vasoac-
ive hormones.
The localization of NOX5 is of interest in human vessels.
n early lesions, NOX5 seemed in many cases to colocalize
ith endothelial cells. It is conceivable that the cytokine
ilieu present in early atherosclerosis could promote NOX5
xpression in endothelial cells. Studies of cytokine regula-
ion of NOX5 in endothelial cells would be informative in
his regard. In moderately advanced lesions, endothelial
taining was less evident; however, a large amount of NOX5
olocalized with vascular smooth muscle cells in subintimal
egions. Complex regions show extensive NOX5 staining in
he area of plaque. The presence of NOX5 in early lesions
nd its loss in advanced lesions is reminiscent of the
xpression of the endothelial nitric oxide synthase in these
ettings, as it is present in early lesions and is lost in
ndothelial cells overlying advanced plaques (20).
In prior studies, xanthine oxidase, NOX4, and NOX2
ere found to be expressed in coronary arteries with
AD (3). In the conditions of our assays of isolated
ascular membranes, it is unlikely that these enzymes
ould be activated by addition of calcium. In keeping
ith this, siRNA against NOX5 markedly inhibited
alcium-dependent NADPH oxidase activity, whereas
alcium-independent activity remained unchanged. As is
vident from Figure 2A, the calcium-dependent activity
as similar to the calcium-independent activity in CAD
essels, whereas in non-CAD membranes its contribu-
ion was much less. This is in keeping with NOX5
nduction in CAD. Thus, calcium-independent NADPH
xidase activity is increased approximately 2.5-fold,
hereas the increase in calcium-dependent activity is
-fold. This would indicate that the atherosclerotic
ilieu provides a potent stimulus for NOX5.
Our findings could have implications for therapy in the
etting of CAD. Calcium channel antagonists are com-
only used in the treatment of angina and CAD and in
eneral have been associated with improved symptoms and
utcome (21). One of their beneficial effects would be to
educe activation of NOX5 in cells harboring L-type cal-
ium channels, including vascular smooth muscle cells in
esions. Other commonly used vasodilators, including nitro-
asodilators and phosphodiesterase inhibitors, also reduce
ntracellular calcium. In this fashion, these agents might
educe activation of NOX5 in diseased vessels and thus
revent oxidant injury.
eprint requests and correspondence: Dr. David G. Harrison,
639 Pierce Drive, Room 319 WMRB, Emory University Cardi-
logy Division, Atlanta, Georgia 30322. E-mail: dharr02@
mory.edu.
aEFERENCES
1. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell
2001;104:503–16.
2. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets
for novel antioxidant strategies. Drug Discov Today 2006;11:524–33.
3. Guzik TJ, Sadowski J, Guzik B, et al. Coronary artery superoxide
production and NOX isoform expression in human coronary artery
disease. Arterioscler Thromb Vasc Biol 2006;26:333–9.
4. Sorescu D, Weiss D, Lassegue B, et al. Superoxide production and
expression of NOX family proteins in human atherosclerosis. Circu-
lation 2002;105:1429–35.
5. Guzik T, Sadowski J, Kapelak B, et al. Systemic regulation of vascular
NAD(P)H oxidase activity and NOX isoform expression in human
arteries and veins. Arterioscler Thromb Vasc Biol 2004;24:1614–20.
6. Banfi B, Molnar G, Maturana A, et al. A Ca(2)-activated NADPH
oxidase in testis, spleen, and lymph nodes. J Biol Chem 2001;276:
37594–601.
7. BelAiba RS, Djordjevic T, Petry A, et al. NOX5 variants are
functionally active in endothelial cells. Free Radic Biol Med 2007;42:
446–59.
8. Lob H, Rosenkranz AC, Breitenbach T, Berkels R, Drummond G,
Roesen R. Antioxidant and nitric oxide-sparing actions of dihydropy-
ridines and ACE inhibitors differ in human endothelial cells. Phar-
macology 2006;76:8–18.
9. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of
angiotensin II-mediated mitochondrial dysfunction; linking mito-
chondrial oxidative damage and vascular endothelial dysfunction. Circ
Res 2008;102:488–96.
0. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus
UG. Functional analysis of Nox4 reveals unique characteristics com-
pared to other NADPH oxidases. Cell Signal 2006;18:69–82.
1. Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative
stress and endothelial dysfunction in patients with chronic heart
failure: role of xanthine-oxidase and extracellular superoxide dis-
mutase. Circulation 2002;106:3073–8.
2. Jagnandan D, Church JE, Banfi B, Stuehr DJ, Marrero MB, Fulton
DJ. Novel mechanism of activation of NADPH oxidase 5. Calcium
sensitization via phosphorylation. J Biol Chem 2007;282:6494–507.
3. Yang H, Roberts LJ, Shi MJ, et al. Retardation of atherosclerosis by
overexpression of catalase or both Cu/Zn-superoxide dismutase and
catalase in mice lacking apolipoprotein E. Circ Res 2004;95:1075–81.
4. Forstermann U, Gath I, Schwarz P, Closs EI, Kleinert H. Isoforms of
nitric oxide synthase—properties, cellular distribution and expressional
control [review]. Biochem Pharm 1995;50:1321–32.
5. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved
in the breakdown of endothelium-derived vascular relaxing factor.
Nature 1986;320:454–6.
6. Guzik TJ, West N, Pillai R, Taggart D, Channon KM. Nitric oxide
modulates superoxide release and peroxynitrite formation in human
blood vessels. Hypertension 2002;39:1088–94.
7. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for
mammalian peroxidases. J Biol Chem 2000;275:37524–32.
8. Adachi T, Weisbrod RM, Pimentel DR, et al. S-glutathiolation by
peroxynitrite activates SERCA during arterial relaxation by nitric
oxide. Nat Med 2004;10:1200–7.
9. Ritsick DR, Edens WA, Finnerty V, Lambeth JD. Nox regulation of
smooth muscle contraction. Free Radic Biol Med 2007;43:31–8.
0. Wilcox JN, Subramanian RR, Sundell CL, et al. Expression of
multiple isoforms of nitric oxide synthase in normal and atherosclerotic
vessels. Arterioscler Thromb Vasc Biol 1997;17:2479–88.
1. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive
agents on cardiovascular events in patients with coronary disease and
normal blood pressure: the CAMELOT study: a randomized con-
trolled trial. JAMA 2004;292:2217–25.
ey Words: reactive oxygen species y NOX5 y NADPH oxidase y
therosclerosis y coronary artery disease.
